Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) has announced a public webcast featuring a discussion with Albert Bourla, Chairman and CEO, at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 10:30 a.m. EST.
The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be posted within 24 hours after the live discussion and remain accessible for at least 90 days.
The discussion may include forward-looking statements about Pfizer's operating performance, product pipeline, business strategy, COVID-19 response, and ESG priorities. These statements are subject to risks and uncertainties as detailed in Pfizer's Annual Report on Form 10-K and subsequent SEC filings.
Summit Therapeutics (NASDAQ: SMMT) has announced a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to assess ivonescimab with several of Pfizer's vedotin-based ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity. Summit will provide ivonescimab while Pfizer will conduct the studies, with both companies overseeing the trials. Both parties maintain their respective product rights.
The clinical trials are scheduled to begin in mid-2024, with further details to be announced later. The partnership focuses on developing novel mechanisms beyond current available treatments, particularly targeting non-small cell lung cancer and other solid tumors.
Pfizer (NYSE: PFE) announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® in combination with XTANDI® for metastatic castration-resistant prostate cancer (mCRPC). The study showed significant improvement in overall survival across two patient cohorts:
In unselected patients (Cohort 1), the combination therapy achieved a median overall survival of 45.8 months versus 37.0 months with XTANDI and placebo, representing a 20% reduction in death risk and nearly 9-month survival gain. In HRR-mutated patients (Cohort 2), median overall survival was 45.1 months versus 31.1 months with XTANDI and placebo, showing a 38% reduction in death risk and 14-month survival improvement.
The safety profile aligned with known characteristics of both medicines, with common adverse events including anemia, neutropenia, and fatigue. The data has been shared with FDA, EMA, and other global health authorities for potential label updates.
Pfizer (NYSE: PFE) has received FDA approval for ADCETRIS® combination therapy for treating relapsed/refractory large B-cell lymphoma (LBCL). The approval is based on the Phase 3 ECHELON-3 trial results, which showed the ADCETRIS regimen reduced death risk by 37% compared to standard treatment.
The therapy is specifically approved for adult patients with LBCL who have undergone two or more lines of systemic therapy and are not eligible for stem cell transplantation or CAR-T therapy. This marks ADCETRIS's eighth FDA-approved indication.
The ECHELON-3 study demonstrated significant improvement in overall survival, with benefits consistent across CD30 expression levels. More than 3,500 patients annually in the U.S. experience treatment failure after two prior therapy lines for this aggressive form of non-Hodgkin lymphoma.
Pfizer (PFE) and Astellas announced extended follow-up results from their Phase 3 EV-302 trial, evaluating PADCEV® plus KEYTRUDA® in first-line treatment of locally advanced or metastatic urothelial cancer. After 29.1 months of median follow-up, the combination therapy showed significant improvements over chemotherapy:
- Reduced death risk by 49% (HR = 0.51)
- Median overall survival: 33.8 months vs 15.9 months for chemotherapy
- Reduced disease progression risk by 52% (HR = 0.48)
- Median progression-free survival: 12.5 months vs 6.3 months for chemotherapy
The confirmed objective response rate was 67.5% for the combination vs 44.2% for chemotherapy, with complete response rates of 30.4% vs 14.5% respectively. The safety profile remained consistent with previous findings, with no new concerns identified.
Pfizer (PFE) reported strong financial results for full-year 2024, with revenues of $63.6 billion, showing 7% year-over-year operational growth. Excluding Paxlovid and Comirnaty contributions, revenues grew 12% operationally.
Fourth-quarter 2024 revenues reached $17.8 billion, with 21% operational growth excluding COVID products. The company reported full-year 2024 adjusted diluted EPS of $3.11 and fourth-quarter adjusted diluted EPS of $0.63.
Pfizer reaffirmed its 2025 financial guidance, projecting revenues between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company is on track to deliver overall net cost savings of approximately $4.5 billion by end of 2025 from its ongoing cost realignment program.
Pfizer (PFE) announced positive topline results from the Phase 3 BREAKWATER study of BRAFTOVI® combination therapy for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The study demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy.
The BRAFTOVI combination regimen, which includes cetuximab and mFOLFOX6, received accelerated FDA approval in December 2024 for treatment-naïve patients based on improved objective response rate (ORR). The safety profile remained consistent with known profiles of each agent, with no new safety signals identified.
These results will be shared with the FDA to support potential conversion to full approval and with other global regulatory authorities for additional license applications.
Pfizer (PFE) will present significant advancements in genitourinary cancer treatments at the ASCO GU Cancers Symposium in San Francisco. The company will showcase more than 20 abstracts, including five oral presentations, focusing on prostate and bladder cancers.
Key highlights include detailed overall survival results from the Phase 3 TALAPRO-2 trial of TALZENNA® with XTANDI® in metastatic castration-resistant prostate cancer, which demonstrated statistically significant improvements. Updated analysis from the Phase 3 EV-302 trial shows sustained overall survival benefits of PADCEV® combined with pembrolizumab in advanced urothelial cancer.
The company will also present the first randomized progression-free survival data for mevrometostat with XTANDI in mCRPC. Pfizer's genitourinary portfolio includes seven approved medicines across bladder, prostate, and kidney cancers, with TALZENNA-XTANDI combination already approved in over 35 countries globally.
Pfizer (PFE) announced positive Phase 3 BREAKWATER trial results for BRAFTOVI® combination therapy in treating BRAF V600E-mutant metastatic colorectal cancer (mCRC). The trial showed a significantly higher objective response rate of 60.9% compared to 40% with standard chemotherapy.
Key findings include a median duration of response of 13.9 months for the BRAFTOVI combination versus 11.1 months for chemotherapy. Additionally, 22.4% of BRAFTOVI-treated patients maintained response for 12+ months, compared to 11.4% in the chemotherapy group.
While overall survival data is not yet mature, early trends favor the BRAFTOVI combination. The safety profile aligned with known profiles of individual components, with serious treatment-emergent adverse events occurring in 37.7% of BRAFTOVI combination patients versus 34.6% in the chemotherapy group. The FDA granted accelerated approval for this treatment in December 2024.
Pfizer (PFE) announced positive topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, combined with BCG therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint, showing significant improvement in event-free survival compared to BCG alone.
The treatment could potentially be the first PD-1 inhibitor approved in combination with BCG for this indication, representing the first major advancement in BCG-naïve, high-risk NMIBC treatment in over 30 years. Approximately 100,000 people globally are diagnosed with high-risk NMIBC annually, with 40-50% experiencing recurrent disease.
The safety profile of sasanlimab with BCG was consistent with known profiles of both treatments. Pfizer plans to submit the results to regulatory authorities and present them at upcoming medical conferences.